OSRHOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as OSRHW
OSR Health, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.21−0.02 (-7.08%)
Close on Oct 19, 2026
- Market cap
- $6.83M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
1M
Shares held, 13F filers
Institutional holders
13
5 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kuk Hyoun Hwang | 2,035,000 | 87.70% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OSRH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Fiduciary Trust Co | 148,266 | – | $46.85K | +131,237 | 0.00% |
| Citadel Advisors LLC | 127,810 | – | $40.43K | New | 0.00% |
| Jane Street Group, LLC | 127,195 | – | $40.23K | New | 0.00% |
| Geode Capital Management, LLC | 100,458 | – | $31.77K | −5,285 | 0.00% |
| Two Sigma Securities, LLC | 46,537 | – | $14.72K | New | 0.00% |
| Vanguard Capital Management LLC | 37,373 | – | $11.81K | – | 0.00% |
| XTX Topco Ltd | 32,380 | – | $10.24K | −28,366 | 0.00% |
| Susquehanna International Group, Llp | 18,282 | – | $5.78K | New | 0.00% |
| Northern Trust Corp | 10,906 | – | $3.45K | New | 0.00% |
| Mint Tower Capital Management B.V. | 7,500 | – | $2 | – | 0.00% |
| Tower Research Capital LLC (TRC) | 6,587 | – | $2.08K | +2,446 | 0.00% |
| UBS Group AG | 580 | – | $183 | −3,896 | 0.00% |
| SBI Securities Co., Ltd. | 137 | – | $43 | +60 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 13 | 1M | 5 / 3 | 3 / 3 | 0M | 0M |
| Q1 2026 | 11 | 0M | 5 / 3 | 2 / 4 | 0M | 0M |
| Q4 2025 | 11 | 0M | 5 / 1 | 2 / 2 | 0M | 0M |
| Q3 2025 | 8 | 0M | 4 / 2 | 0 / 4 | 0M | 0M |
| Q2 2025 | 8 | 0M | 2 / 3 | 1 / 2 | 0M | 0M |
| Q1 2025 | 8 | 0M | 8 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of OSRH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 73,009 | – | $31.80K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 37,373 | – | $11.82K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 6,773 | – | $2.95K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 4,318 | – | $1.88K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Kuk Hyoun Hwang | President and CEO, Director, 10% owner | 24,317,738 | Feb 19, 2025 |
| Yeiseok Kim | Chief Operating Officer | 24,699 | Apr 16, 2026 |
| Sang Harry Kim | See Remarks | – | Feb 21, 2025 |
| Gihyoun Bang | Chief Financial Officer | – | Feb 20, 2025 |
| Reto Kaspar Fierz | Director | – | Oct 24, 2025 |
| Joong Myung Cho | Director | – | Feb 21, 2025 |
| Alcide Barberis | Director | – | Feb 21, 2025 |
| Hyuk Joo Jee | Director | – | Feb 20, 2025 |
| Capital Management LLC Bellevue | 10% owner | 3,123,970 | Feb 19, 2025 |
| Europe AG BCM | 10% owner | 7,531,634 | Feb 19, 2025 |
| Global Life Science Investors LLC Bellevue | 10% owner | 2,043,500 | Feb 19, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2025 | Other | +43,000 | – | – | 2,043,500 |
| Kuk Hyoun Hwang President and CEO, Director, 10% owner | Feb 14, 2025 | Other | +7,531,634 | – | – | 9,575,134 |
| Kuk Hyoun Hwang President and CEO, Director, 10% owner | Feb 14, 2025 | Other | +3,123,970 | – | – | 12,699,104 |
| Kuk Hyoun Hwang President and CEO, Director, 10% owner | Feb 14, 2025 | Other | +43,000 | – | – | 2,043,500 |
| Global Life Science Investors LLC Bellevue 10% owner | Mar 23, 2023 | Other | −20,000 | – | – | 2,000,500 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Mar 23, 2023 | Other | −20,000 | – | – | 2,000,500 |
| David Jin Yoo Chief Financial Officer | Mar 23, 2023 | Award | +20,000 | – | – | 20,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 21, 2023 | Other | −4,500 | – | – | 2,020,500 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 21, 2023 | Other | +225,000 | – | – | 2,025,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 21, 2023 | Other | −4,500 | – | – | 2,020,500 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 21, 2023 | Other | +225,000 | – | – | 2,025,000 |
| Hosun Euh Director | Feb 14, 2023 | Award | +20,000 | – | – | 20,000 |
| Steven Reed Director | Feb 14, 2023 | Award | +20,000 | – | – | 20,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Other | −30,000 | – | – | 1,370,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Other | −225,000 | – | – | 1,400,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,625,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Award | +430,000 | $10.00 | $4.30M | 1,800,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,665,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,685,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,705,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,645,000 |
| Jin Whan Park Director | Feb 14, 2023 | Award | +20,000 | – | – | 20,000 |
| Rad Roberts Director | Feb 14, 2023 | Award | +20,000 | – | – | 20,000 |
| In Chul Chung Director | Feb 14, 2023 | Award | +20,000 | – | – | 20,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,645,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Other | −30,000 | – | – | 1,370,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Other | −225,000 | – | – | 1,400,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,625,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Award | +430,000 | $10.00 | $4.30M | 1,800,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,665,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,685,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,705,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.